NSF's Budget Falls Short Of Requested Hike

WASHINGTON—Although House and Senate conferees compromised on the higher of two numbers in all parts of the National Science Foundation’s 1990 budget, scientists will still be getting less than President Bush requested for the foundation last February. And the repeated promise of a doubling of the NSF budget within five years is likely once again to ring hollow in their ears. The October 17 agreement, which must he approved separately by each house and by the president, gives NS

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—Although House and Senate conferees compromised on the higher of two numbers in all parts of the National Science Foundation’s 1990 budget, scientists will still be getting less than President Bush requested for the foundation last February. And the repeated promise of a doubling of the NSF budget within five years is likely once again to ring hollow in their ears.

The October 17 agreement, which must he approved separately by each house and by the president, gives NSF a total of $2.103 billion, an increase of $218 million (11.6%) over 1989. However, a 1.5% across-the-board tax, to fund the new war on drugs and to meet 1990 budget limits, reduces that amount by $31 million. An additional cut of 5.3%, triggered by the Gramm-Rudman-Hollings act to reduce the federal deficit, would become permanent if the appropriations bill for NSF and several other government agencies does not become law.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies